Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
17 studies found for:    GDC-0941
Show Display Options
Rank Status Study
1 Completed A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Condition: Solid Cancers
Intervention: Drug: GDC-0941
2 Completed A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: GDC-0941;   Drug: Placebo;   Drug: Paclitaxel
3 Completed A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
Condition: Non-Hodgkin's Lymphoma, Solid Cancers
Intervention: Drug: GDC-0941
4 Terminated GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
5 Completed A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors
Condition: Non-Squamous Non-Small Cell Lung Cancer, Solid Cancers
Interventions: Drug: GDC-0941;   Drug: erlotinib HCl
6 Completed A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers
Condition: Healthy Volunteers
Interventions: Drug: GDC-0941;   Drug: rabeprazole
7 Completed A Study to Determine the Relative Bioavailability of a Tablet Formulation of GDC-0941 and the Effect of Ketoconazole on the Pharmacokinetics of the GDC-0941 Tablet
Condition: Healthy Volunteer
Interventions: Drug: GDC-0941;   Drug: ketoconazole
8 Completed Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy
Condition: Breast Cancer
Interventions: Drug: Fulvestrant;   Drug: GDC-0941;   Drug: GDC-0941 Matching Placebo;   Drug: GDC-0980;   Drug: GDC-0980 Matching Placebo
9 Terminated
Has Results
Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Cobimetinib;   Drug: Pictilisib
10 Completed A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer
Condition: Non-Squamous Non-Small Cell Lung Cancer
Interventions: Drug: GDC-0941;   Drug: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel;   Drug: pemetrexed
11 Completed A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Bevacizumab;   Drug: Pictilisib;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Trastuzumab
12 Completed Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy
Condition: Metastatic Breast Cancer
Interventions: Drug: GDC-0941;   Drug: Trastuzumab;   Drug: trastuzumab-MCC-DM1
13 Completed Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects
Condition: Healthy Volunteer
Intervention: Drug: GDC-0941
14 Completed A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: GDC-0941
15 Completed Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: pictilisib;   Drug: Placebo;   Drug: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel
16 Recruiting PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib
Conditions: Advanced Solid Tumours;   Breast Cancer
Intervention: Drug: Palbociclib + Taselisib / Pictilisib
17 Enrolling by invitation Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Condition: Glioblastoma
Interventions: Drug: MK - 3475;   Biological: Suppressor of the PI3K/Akt pathways

Study has passed its completion date and status has not been verified in more than two years.